JPRN-jRCT2080221110未知2 期
Phase II/III induction study of AJG501 in patients with active ulcerative colitis
Ajinomoto Pharmaceuticals Co., Ltd.0 个研究点开始时间: 2010年5月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Baseline Revised Sutherland DAI score of 4-8 including abnormal rectal bleeding score
排除标准
- 未提供
研究者
相似试验
未知
3 期
Phase III study of AJG511 in patients with active ulcerative colitisulcerative colitisJPRN-jRCT2080222653EA Pharma Co.,Ltd.120
未知
2 期
Phase II study of AJG511 in patients with active ulcerative colitislcerative colitisJPRN-jRCT2080222245Ajinomoto Pharmaceuticals Co., Ltd.
未知
3 期
Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5Patients scheduled for colonoscopyJPRN-jRCT2080221438Ajinomoto Pharmaceuticals Co., Ltd.
未知
2 期
Phase II/III maintenance study of AJG501 in patients with ulcerative colitislcerative colitisJPRN-jRCT2080221044Ajinomoto Pharmaceuticals Co., Ltd.
未知
2 期
Phase-IIa Study of AJM300 in Patients with Active Ulcerative Colitislcerative ColitisJPRN-jRCT2080222244Ajinomoto Pharmaceuticals Co., Ltd.